# Tanezumab in Osteoarthritis Of The Hip

> **NCT00744471** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 627 (actual)

## Conditions studied

- Arthritis
- Osteoarthritis
- Osteoarthritis, Hip

## Interventions

- **BIOLOGICAL:** tanezumab
- **BIOLOGICAL:** tanezumab
- **BIOLOGICAL:** tanezumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00744471
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11-17
- **Primary completion:** 2010-03-15
- **Final completion:** 2010-08-13
- **Target enrollment:** 627 (ACTUAL)
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00744471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00744471, "Tanezumab in Osteoarthritis Of The Hip". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00744471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*